Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report

Shixuan Zhang,1 Panpan Liu,2 Sitong Liu,1 Minghuan He,1 Song Zheng,3 Xiaodong Sun,4 Ruiqun Qi,3,5 Xinghua Gao,3,5 Lili Zhu1 1Department of Dermatology, the People’s Hospital of Liaoning Province, Shenyang, Liaoning Province, 110016, People’s Republic of China; 2Department of Nephrology, the People’s Hospital of Liaoning Province, Shenyang, Liaoning Province, 110016, People’s Republic of China; 3Department of Dermatology, the First Hospital of China Medical University, Shenyang, Liaoning Province, 110000, People’s Republic of China; 4Department of Dermatology, Shenyang No. 7 People’s Hospital, Shenyang, Liaoning Province, 110000, People’s Republic of China; 5Key Laboratory of Immunodermatology, Ministry of Education, and National Health Commission; National Joint Engineering Research Center for Theranostics of Immunological Skin Diseases, Shenyang, 110000, People’s Republic of ChinaCorrespondence: Lili Zhu, Department of Dermatology, the People’s Hospital of Liaoning Province, Shenyang, 110016, People’s Republic of China, Tel +86-024-24016951, Fax +86-024-24016585, Email [email protected]: Patients with erythrodermic psoriasis (EP) complicated by end-stage renal disease (ESRD) requiring hemodialysis are extremely rare in clinical practice, and treatment options for this specific population remain highly limited. Herein we report a case of an EP patient with ESRD, in whom treatment with an interleukin-17 (IL-17) inhibitor secukinumab not only rapidly alleviated erythrodermic symptoms but also resulted in a certain degree of improvement in renal function. At the 7-month follow-up, the patient maintained skin lesion clearance with no deterioration in renal function—a finding that has not been consistently documented in previous literature. This case suggests that for patients with psoriasis complicated by kidney disease IL-17 inhibitors may serve as a potentially favorable therapeutic option.Keywords: erythrodermic psoriasis, end-stage renal disease, IL-17 inhibitor case report